NCT00006243 arm group 573e943f32ceebbf5f3a1f48606d4518 [clinicaltrials_resource:NCT00006243/arm-group/573e943f32ceebbf5f3a1f48606d4518]
MART-1:27-35 peptide vaccine [clinicaltrials_resource:08df0a9c4b1128982b34b22ed35a32f4]gp100 antigen [clinicaltrials_resource:5847d149f0f0c99784aabdf8490f002b]laboratory biomarker analysis [clinicaltrials_resource:788bdef1603000e973c1cebc9a13c333]sargramostim [clinicaltrials_resource:cda122d8698c2776b7627caee368c5cb]incomplete Freund's adjuvant [clinicaltrials_resource:df5d172b8063ce4bda85cab1a7cb6c0d]tyrosinase peptide [clinicaltrials_resource:eec622bde175cde826998c1e5ff11252]Vaccine Therapy and Sargramostim in Treating Patients With Stage IV Malignant Melanoma [clinicaltrials:NCT00006243]
arm group [clinicaltrials_vocabulary:arm-group]
NCT00006243 arm group 573e943f32ceebbf5f3a1f48606d4518 [clinicaltrials_resource:NCT00006243/arm-group/573e943f32ceebbf5f3a1f48606d4518]
Bio2RDF identifier
NCT00006243/arm-group/573e943f32ceebbf5f3a1f48606d4518
Bio2RDF namespace
clinicaltrials_resource
Bio2RDF uri
http://bio2rdf.org/clinicaltri ...... 3e943f32ceebbf5f3a1f48606d4518
description [clinicaltrials_vocabulary:description]
Patients receive tyrosinase pe ...... weeks 0, 3, 6, 9, 12, and 24.
identifier
clinicaltrials_resource:NCT00006243/arm-group/573e943f32ceebbf5f3a1f48606d4518
title
NCT00006243 arm group 573e943f32ceebbf5f3a1f48606d4518
@en
type
label
NCT00006243 arm group 573e943f ...... e943f32ceebbf5f3a1f48606d4518]
@en